Keywords: Geron Corp, BioTime, Letter of intent, Stem cell program, Shares, Warrants

Geron signs tentative deal with BioTime on stem cell assets

Article | 18 November 2012

Print This

A year after announcing its decision to exit stem cell therapy, the USA’s Geron Corp (Nasdaq: GERN) has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in